Difficult to understand this market. One of only three players (Pathwork Diagnostics) appears to be no longer accepting specimens for their test. They indicate this is temporary until / and if they receive additional financing. The leading player, bioTheranostics, appears to be picking up a fair amount of the Pathwork Diagnostics business or at least that is the street story.
Agency for Healthcare Research and Quality released its Technical Assessment Study (today) entitled "Technology Assessment on Genetic Testing in Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin". Study compares/evaluates all three commercially available tests. Significant study, 88 pages. Read and make your own decision. WorldWideWeb.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdk
ROSG price per share has nothing to do with anything like earnings or news. The crooks who manipulate this stock will pump it on anything EXCEPT news. The SEC is the biggest joke agency in the US government for letting people steal right under their noses. When institutional holders decide this stock should be at $15 again, it will be, until then sales, earnings, patents, and all other news is worth about a $.20 spike at open for about 2 hours before its driven back down.